Related Experiment Video
Updated: May 26, 2026

Using the Overlay Assay to Qualitatively Measure Bacterial Production of and Sensitivity to Pneumococcal Bacteriocins
Published on: September 30, 2014
Development of Class IIa Bacteriocins as Therapeutic Agents
Christopher T Lohans1, John C Vederas
1Department of Chemistry, University of Alberta, Edmonton, AB, Canada T6G 2G2.
Abstract:
Class IIa bacteriocins have been primarily explored as natural food preservatives, but there is much interest in exploring the application of these peptides as therapeutic antimicrobial agents. Bacteriocins of this class possess antimicrobial activity against several important human pathogens. Therefore, the therapeutic development of these bacteriocins will be reviewed. Biological and chemical modifications to both stabilize and increase the potency of bacteriocins are discussed, as well as the optimization of their production and purification. The suitability of bacteriocins as pharmaceuticals is explored through determinations of cytotoxicity, effects on the natural microbiota, and in vivo efficacy in mouse models. Recent results suggest that class IIa bacteriocins show promise as a class of therapeutic agents.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Clinical Significance of Antibiotic Resistance
Inhibitors of Bacterial Protein Synthesis
Biological Methods for Microbial Control
Development of Antibiotic Resistance
Gene Regulation in Microbial Communities: Quorum Sensing

